Embree Financial Group Acquires 178 Shares of Eli Lilly and Company (NYSE:LLY)

Embree Financial Group boosted its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 26.0% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 862 shares of the company’s stock after purchasing an additional 178 shares during the quarter. Embree Financial Group’s holdings in Eli Lilly and Company were worth $671,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the business. Norges Bank purchased a new position in Eli Lilly and Company during the 4th quarter valued at approximately $5,992,890,000. International Assets Investment Management LLC raised its position in Eli Lilly and Company by 61,268.8% during the 4th quarter. International Assets Investment Management LLC now owns 7,342,780 shares of the company’s stock valued at $42,802,530,000 after purchasing an additional 7,330,815 shares in the last quarter. Sapient Capital LLC bought a new position in shares of Eli Lilly and Company in the 4th quarter worth $682,139,000. Vanguard Group Inc. raised its position in shares of Eli Lilly and Company by 0.9% in the 3rd quarter. Vanguard Group Inc. now owns 70,575,602 shares of the company’s stock worth $37,908,273,000 after acquiring an additional 659,838 shares in the last quarter. Finally, Comerica Bank bought a new position in shares of Eli Lilly and Company in the 3rd quarter worth $345,781,000. Institutional investors own 82.53% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts recently weighed in on LLY shares. Barclays boosted their target price on Eli Lilly and Company from $913.00 to $1,025.00 and gave the stock an “overweight” rating in a research note on Wednesday. JPMorgan Chase & Co. raised their price target on shares of Eli Lilly and Company from $900.00 to $1,000.00 and gave the stock an “overweight” rating in a report on Thursday. Citigroup increased their price objective on shares of Eli Lilly and Company from $675.00 to $895.00 and gave the stock a “buy” rating in a research report on Tuesday, April 2nd. Morgan Stanley reissued an “overweight” rating and issued a $1,023.00 price target on shares of Eli Lilly and Company in a research report on Friday, July 5th. Finally, BMO Capital Markets reissued an “outperform” rating and issued a $1,001.00 price target on shares of Eli Lilly and Company in a research report on Wednesday, July 3rd. Three research analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $834.28.

Insider Buying and Selling

In related news, major shareholder Lilly Endowment Inc sold 92,563 shares of the company’s stock in a transaction that occurred on Friday, May 24th. The shares were sold at an average price of $809.21, for a total transaction of $74,902,905.23. Following the completion of the transaction, the insider now owns 98,556,247 shares of the company’s stock, valued at $79,752,700,634.87. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. In other news, major shareholder Lilly Endowment Inc sold 92,563 shares of the stock in a transaction on Friday, May 24th. The shares were sold at an average price of $809.21, for a total value of $74,902,905.23. Following the completion of the sale, the insider now owns 98,556,247 shares of the company’s stock, valued at $79,752,700,634.87. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Johna Norton sold 7,056 shares of the company’s stock in a transaction on Monday, June 3rd. The shares were sold at an average price of $819.38, for a total transaction of $5,781,545.28. Following the completion of the transaction, the executive vice president now owns 25,428 shares of the company’s stock, valued at $20,835,194.64. The disclosure for this sale can be found here. Over the last quarter, insiders sold 1,004,704 shares of company stock valued at $869,479,116. Insiders own 0.13% of the company’s stock.

Eli Lilly and Company Price Performance

Shares of NYSE LLY traded down $18.90 on Thursday, hitting $920.88. The company’s stock had a trading volume of 1,292,630 shares, compared to its average volume of 2,924,671. Eli Lilly and Company has a 12-month low of $434.34 and a 12-month high of $945.69. The company has a market capitalization of $875.21 billion, a price-to-earnings ratio of 138.08, a price-to-earnings-growth ratio of 2.00 and a beta of 0.41. The company has a debt-to-equity ratio of 1.90, a current ratio of 1.35 and a quick ratio of 1.03. The stock has a 50 day moving average of $841.60 and a 200-day moving average of $758.80.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings data on Monday, May 6th. The company reported $2.58 earnings per share for the quarter, beating analysts’ consensus estimates of $2.53 by $0.05. The business had revenue of $8.77 billion during the quarter, compared to analyst estimates of $8.94 billion. Eli Lilly and Company had a net margin of 17.08% and a return on equity of 56.98%. The company’s revenue was up 26.0% on a year-over-year basis. During the same quarter in the previous year, the business posted $1.62 earnings per share. As a group, research analysts predict that Eli Lilly and Company will post 13.76 EPS for the current year.

Eli Lilly and Company Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, September 10th. Investors of record on Thursday, August 15th will be given a dividend of $1.30 per share. This represents a $5.20 annualized dividend and a yield of 0.56%. The ex-dividend date of this dividend is Thursday, August 15th. Eli Lilly and Company’s dividend payout ratio (DPR) is 76.58%.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.